Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The mode of action of Herceptin activates the body's immune system and suppresses HER2 signalling to target and destroy the tumour. The drug was first approved in 1998 and has been used to treat ...

Phesgo combines the anti-HER2 antibodies in Herceptin (trastuzumab) and Perjeta (pertuzumab) in a subcutaneous injection that takes a few minutes to deliver. At the moment, Herceptin is available ...